|
|
|
Volumn 18, Issue 13 Suppl 7, 2004, Pages 24-29
|
|
Combination antifungal therapy: where are we now, and where are we going?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPHOTERICIN B;
ANTIFUNGAL AGENT;
CASPOFUNGIN;
CYCLOPEPTIDE;
FLUCONAZOLE;
LIPOPROTEIN;
MICAFUNGIN;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
TRIAZOLE DERIVATIVE;
VORICONAZOLE;
ANIMAL;
ASPERGILLOSIS;
CANDIDIASIS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DISEASE MODEL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG COMBINATION;
HUMAN;
IN VITRO STUDY;
MYCOSIS;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
TIME;
TREATMENT OUTCOME;
AMPHOTERICIN B;
ANIMALS;
ANTIFUNGAL AGENTS;
ASPERGILLOSIS;
AZOLES;
CANDIDIASIS;
DISEASE MODELS, ANIMAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FLUCONAZOLE;
HUMANS;
LIPOPROTEINS;
MYCOSES;
PEPTIDES, CYCLIC;
PYRIMIDINES;
RANDOMIZED CONTROLLED TRIALS;
TIME FACTORS;
TREATMENT OUTCOME;
TRIAZOLES;
|
|
EID: 13944278870
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (34)
|
|
References (23)
|
